Current PD treatment is symptomatic and primarily involves pharmacological therapies including DA replacement with synthetic DA agonists such as levodopa and with drugs that increase the DA supply by inhibiting catechol-O-methyl transferase and monoamine oxidase B (MAO-B) [3]. Here, MAOB is linked to Parkinson disease.